Kenan Turnacioglu

Board Member

2022

Board Member

2020

Member Board Of Directors

2020 - 2022

Board Member

2020 - 2022

Chair Of The Board Of Directors

2017

· Company spun out of Memorial Sloan Kettering with goal of applying machine · Learning/artificial intelligence to supplement the pathologist in diagnosis.

General Partner & Member of the Investment Committee

2020 - 2021

Catalio Capital Management invests in breakthrough biomedical technologies companies around the globe.

Founding Partner

2011 - 2018

· Founding Partner of Firm that was launched with $4.25bn in assets and grew to $10bn · Managed on average $2bn in capital in Healthcare, Consumer, and TMT · Oversaw the development of the firms Technology and Media group · Oversaw the development of a data science team to analyze large data set · Returns of mid-teens from 2011 to 2017 · Departed firm at end of 2017 to retire from money management business

Executive Board Member

2013 - 2016

· Company focused on cancer stem cells as targets for antibody therapeutics · Valuation at the time of sale to Abbvie $6.2BN with potential of CVR $4.0BN

Portfolio Manager

2001 - 2010

· Portfolio Manager covering Global Healthcare Industry · Started out as an analyst covering biotech · Portfolio Manager covering Global Healthcare Industry mid-teens returns · Company dissolved in 2010 with the retirement of Founder, Stanley Druckenmiller

Executive Board Member

2004 - 2007

· Company focused on developing antibody therapeutics for cancer targets · Valuation at the time of sale to Astellas was $527mm

Research associate

1999 - 2001

· Research associate covering the biotechnology sector · Initiated on several genomic and antibody companies